EGLN1 and neoplasm: 20% of Tyr::CreER; BRafV600E; Phd2−/− mice developed tumor outside the area treated with 4-OHT, while none of the Tyr::CreER; BRafV600E; Phd2-/+ mice developed tumor outside the area treated with 4-OHT (Fig. 4k).